Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Rosetta Inpharmatics (RSTA) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (27)	4/18/2001 9:21:15 AM
From: nigel bates	Read Replies (1) \| Respond to of 31

KIRKLAND, Wash.--(BUSINESS WIRE)--April 18, 2001--Rosetta Inpharmatics, Inc. (Nasdaq:RSTA - news) today announced that the University of Washington has licensed the Rosetta Resolver Gene Expression Data Analysis System. The Rosetta Resolver system is an enterprise-level bioinformatics system for gene expression research developed by Rosetta Inpharmatics and exclusively distributed by Agilent Technologies, Inc. (NYSE:A - news). The Rosetta Resolver system licensed by the University of Washington to analyze gene expression data can be used with a variety of third party and internally developed DNA chip technologies, including Agilent DNA microarrays and Affymetrix GeneChip® microarrays. The University of Washington is widely recognized for the advancement of medical knowledge through scientific research and education. Research pursued by faculty at the University may use the Rosetta Resolver system for such diverse areas as the determination of the chemical basis of behavior, the molecular nature of embryological development, and the pathogenesis of disease...